US awards Novartis’ Kisqali ‘Breakthrough’ status
admin 3rd January 2018 Uncategorised 0Novartis’ CDK4/6 inhibitor Kisqali has picked up Breakthrough status in the US as an initial endocrine-based treatment in certain patients with breast cancer.
More: US awards Novartis’ Kisqali ‘Breakthrough’ status
Source: News